about
Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn's diseaseGlucose intolerance and diabetes mellitus in ulcerative colitis: pathogenetic and therapeutic implicationsPrevalence of anemia in inflammatory bowel diseases in european countries: a systematic review and individual patient data meta-analysis.Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis.Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment.Editor's quiz: Sigmoid stricture in a 39-year-old female.Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow TransplantationAppropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.Biologic therapy for inflammatory bowel disease.Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease.Perianal Crohn's disease: overview.Review article: the management of steroid dependency in ulcerative colitis.Replication of interleukin 23 receptor and autophagy-related 16-like 1 association in adult- and pediatric-onset inflammatory bowel disease in Italy.HLA and autoimmune digestive disease: a clinically oriented review for gastroenterologists.Role of the advanced glycation end products receptor in Crohn's disease inflammation.Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus.Vitamin D and inflammatory bowel disease.Immunosuppressive and biologic therapy for ulcerative colitis.Immunogenicity and autoimmunity during anti-TNF therapy.Ulcerative colitis: current pharmacotherapy and future directions.Overview of biological therapy in ulcerative colitis: current and future directions.Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study".The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study.Long-term outcome of inflammatory bowel diseases with cytomegalovirus colitis: effect of antiviral treatment.Crohn's disease loci are common targets of protozoa-driven selection.Monocyte-derived dendritic cells from Crohn patients show differential NOD2/CARD15-dependent immune responses to bacteria.An evolutionary analysis of RAC2 identifies haplotypes associated with human autoimmune diseases.Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study.Combined therapeutic approach: inflammatory bowel diseases and peripheral or axial arthritis.Transperineal perineal ultrasound versus magnetic resonance imaging in the assessment of perianal Crohn's disease.Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines.Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial.Infliximab-induced lupus in Crohn's disease: a case report.Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study.Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease.Validation of the Italian translation of the Inflammatory Bowel Disease Questionnaire.Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006.Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.Sympathetic overactivity in active ulcerative colitis: effects of clonidine.
P50
Q26745717-9A4794F9-2AC2-4555-850D-495EC17BA29AQ26866110-E2C96A53-7189-4717-8DAA-26B1C59A8ACFQ30765230-135435C1-8078-40B2-BD06-2468CDC08BC8Q33476786-767FF944-C80C-4915-A1E3-954150F5F006Q33632204-171377B3-7BE9-4A21-A47D-B0BD2D52E4FDQ35954127-EF23A5AD-4B20-4B35-9050-05BDF37D58EDQ36020897-075D8CE7-9195-4E1A-AFCF-621D926143F9Q36127192-B2948119-15FB-4DB6-A668-37F1F185A3CAQ36304789-E7CF1855-A461-45CD-B653-37548FED7473Q36847655-3E361283-6844-47E9-87EB-549106E26F92Q36920846-8F3FBD56-7340-4D3C-B26A-E67E689F00C4Q36927636-5A290054-BF64-4AC1-B081-09D1142E50CCQ37335103-06F9A6F9-E9B4-47EA-BA14-4B7105FE052BQ37355718-ECC8CD3A-D98C-4B4D-9295-200E6F2179EAQ37378925-FE881BDE-F05A-4F67-A32E-5D786CEA7DFFQ37545775-658B21DA-4433-4400-B426-568BF0F8A03AQ37854972-9364151A-80CA-4FCA-9C62-67D0CE358D2FQ38060831-D426B807-DFAC-49DA-AB12-37BC6679F9D6Q38064661-40647261-94FB-422D-9534-9286AC3C46FBQ38217653-558901CC-B834-4248-8070-7628C6FBDDC9Q38538390-1433B615-2726-49AF-B5F7-712A74F49998Q38813556-23653F50-DBE2-494D-BCE8-9469A2653147Q39018436-ABEF2F23-6276-42AF-814F-70291F126D45Q40877160-EC6B63FA-3E42-457D-B26A-52894F885D3AQ42202120-8C5C82DC-E33B-4FD5-AD57-042889B997B7Q42275989-48B68A2F-B0C0-4DA5-8116-B2371B998BCCQ42524253-2AA0F5C7-222A-444F-8EFF-F6ED8578A45CQ42605359-BCCDF8B5-B815-4431-9FF3-072A6ED0C52CQ42994290-C00634AB-C1A3-4630-94AF-5E68D989D544Q43066415-42934B7D-D295-4059-A7CF-8DDE4B7C0820Q43838432-AA78E6FF-7800-4F38-8E56-C82BB3EA9535Q44186458-2F1DA88C-6BDB-4485-83EF-7CE69B9FE73AQ44290404-15856440-FF33-4662-BDB5-AE5F0D9740B0Q44692619-9B991600-9D2D-437E-B6BC-49E8D90425BCQ45038407-9C29AEDB-8274-403F-917D-6C634E586502Q45054685-BA7468F0-F80B-400A-A87A-8D7303806EC0Q45347419-1C0210F9-7FDA-44D1-87E0-6D30DC3160ADQ45741361-1605BCBE-490B-4280-8EDC-322E7BC66FCDQ45899366-3248A132-9B34-4949-80E9-6DB88903059BQ46669979-0762B184-5C49-470E-9DDF-A763701799CA
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sandro Ardizzone
@ast
Sandro Ardizzone
@en
Sandro Ardizzone
@es
Sandro Ardizzone
@nl
type
label
Sandro Ardizzone
@ast
Sandro Ardizzone
@en
Sandro Ardizzone
@es
Sandro Ardizzone
@nl
prefLabel
Sandro Ardizzone
@ast
Sandro Ardizzone
@en
Sandro Ardizzone
@es
Sandro Ardizzone
@nl
P106
P1153
7005068246
P21
P31
P496
0000-0001-9915-2992